Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A.

Bioorg Med Chem Lett

Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., PO Box 2000, Rahway, NJ 07065-0900, USA.

Published: September 2008

Pyrazolopyrimidines were discovered as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A. In addition to its intrinsic activity, compound 9n significantly enhances nicotinic acid binding to the receptor, thereby potentiating the functional efficacy of nicotinic acid.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2008.08.039DOI Listing

Publication Analysis

Top Keywords

nicotinic acid
16
class allosteric
8
allosteric agonists
8
agonists high
8
high affinity
8
affinity nicotinic
8
acid receptor
8
receptor gpr109a
8
discovery pyrazolopyrimidines
4
pyrazolopyrimidines class
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!